Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company, has announced it will host a conference call and live webcast on August 8, 2024, at 8:30 a.m. ET. The event will provide a corporate update and discuss the company's financial results for the second quarter ended June 30, 2024. Investors can access the live audio webcast through the company's website, www.avadel.com. A replay will be available for 90 days following the event. Participants are encouraged to register for the conference call in advance, at least 10 minutes prior to the start time.
Avadel Pharmaceuticals plc (Nasdaq: AVDL), un'azienda biopharmaceutical, ha annunciato che ospiterà una conference call e una trasmissione web dal vivo il 8 agosto 2024, alle 8:30 a.m. ET. L'evento fornirà un aggiornamento aziendale e discuterà i risultati finanziari del secondo trimestre chiuso il 30 giugno 2024. Gli investitori possono accedere alla trasmissione audio dal vivo attraverso il sito web dell'azienda, www.avadel.com. Una registrazione sarà disponibile per 90 giorni dopo l'evento. I partecipanti sono incoraggiati a registrarsi in anticipo per la conference call, almeno 10 minuti prima dell'orario di inizio.
Avadel Pharmaceuticals plc (Nasdaq: AVDL), una compañía biofarmacéutica, ha anunciado que llevará a cabo una conferencia telefónica y una transmisión web en vivo el 8 de agosto de 2024, a las 8:30 a.m. ET. El evento proporcionará una actualización corporativa y discutirá los resultados financieros del segundo trimestre que terminó el 30 de junio de 2024. Los inversores pueden acceder a la transmisión de audio en vivo a través del sitio web de la empresa, www.avadel.com. Una grabación estará disponible durante 90 días después del evento. Se recomienda a los participantes que se registren para la conferencia telefónica con anticipación, al menos 10 minutos antes de la hora de inicio.
Avadel Pharmaceuticals plc (Nasdaq: AVDL), 생물 의약품 회사는 2024년 8월 8일 오전 8시 30분 ET에 전화 회의 및 실시간 웹 콜을 개최한다고 발표했습니다. 이 행사는 기업 업데이트를 제공하고 2024년 6월 30일 종료된 2분기 재무 결과에 대해 논의할 것입니다. 투자자는 회사 웹사이트 www.avadel.com을 통해 실시간 오디오 웹캐스트에 접근할 수 있습니다. 이벤트 후 90일 동안 다시 보기가 가능합니다. 참가자는 시작 시간보다 최소 10분 전에 회의에 사전 등록하는 것이 권장됩니다.
Avadel Pharmaceuticals plc (Nasdaq: AVDL), une société biopharmaceutique, a annoncé qu'elle tiendra une conférence téléphonique et une diffusion en direct le 8 août 2024 à 8h30 ET. Cet événement fournira une mise à jour de l'entreprise et discutera des résultats financiers du deuxième trimestre clos le 30 juin 2024. Les investisseurs peuvent accéder à la diffusion audio en direct via le site web de l'entreprise, www.avadel.com. Un enregistrement sera disponible pendant 90 jours après l'événement. Les participants sont encouragés à s'inscrire à l'avance pour la conférence téléphonique, au moins 10 minutes avant le début.
Avadel Pharmaceuticals plc (Nasdaq: AVDL), ein biopharmazeutisches Unternehmen, hat angekündigt, dass am 8. August 2024 um 8:30 Uhr ET eine Telefonkonferenz und ein Live-Webcast stattfinden werden. Bei der Veranstaltung werden ein Unternehmensupdate sowie die Finanzergebnisse für das zweite Quartal zum 30. Juni 2024 besprochen. Investoren können auf den Live-Audio-Webcast über die Unternehmenswebsite www.avadel.com zugreifen. Eine Wiederholung wird 90 Tage nach der Veranstaltung verfügbar sein. Teilnehmer werden ermutigt, sich im Voraus, mindestens 10 Minuten vor Beginn, für die Telefonkonferenz anzumelden.
- None.
- None.
DUBLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 8, 2024, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2024.
A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Courtney Mogerley
Precision AQ
Courtney.Mogerley@precisionAQ.com
(212) 698-8687
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
When will Avadel Pharmaceuticals (AVDL) report its Q2 2024 financial results?
How can investors access Avadel Pharmaceuticals' (AVDL) Q2 2024 earnings call?
Will there be a replay available for Avadel Pharmaceuticals' (AVDL) Q2 2024 earnings call?
What period will Avadel Pharmaceuticals' (AVDL) Q2 2024 financial results cover?
